Casdin Capital’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-863,300
| Closed | -$83.7M | – | 35 |
|
|
2019
Q3 | $83.7M | Sell |
863,300
-21,500
| -2% | -$2.15M | 8.66% | 1 |
|
|
2019
Q2 | $90.6M | Sell |
884,800
-55,200
| -6% | -$5.96M | 8.48% | 1 |
|
|
2019
Q1 | $107M | Buy |
940,000
+100,000
| +12% | +$7.35M | 11.76% | 1 |
|
|
2018
Q4 | $32.9M | Buy |
840,000
+165,000
| +24% | +$7.16M | 5.62% | 5 |
|
|
2018
Q3 | $36.8M | Buy |
675,000
+212,000
| +46% | +$14.5M | 4.48% | 10 |
|
|
2018
Q2 | $38.3M | Hold |
463,000
| – | – | 5.36% | 6 |
|
|
2018
Q1 | $30.8M | Buy |
463,000
+160,526
| +53% | +$9.27M | 5.42% | 5 |
|
|
2017
Q4 | $15.6M | Buy |
302,474
+93,000
| +44% | +$6.68M | 3.79% | 13 |
|
|
2017
Q3 | $18.7M | Buy |
209,474
+39,474
| +23% | +$3M | 5.27% | 9 |
|
|
2017
Q2 | $10.2M | Buy |
170,000
+35,000
| +26% | +$1.96M | 3.76% | 10 |
|
|
2017
Q1 | $7.2M | Buy |
135,000
+6,500
| +5% | +$386K | 4.25% | 8 |
|
|
2016
Q4 | $6.41M | Buy |
128,500
+35,000
| +37% | +$1.87M | 5.3% | 7 |
|
|
2016
Q3 | $5.62M | Sell |
93,500
-69,000
| -42% | -$3.98M | 4.55% | 8 |
|
|
2016
Q2 | $8.31M | Sell |
162,500
-7,500
| -4% | -$320K | 8.27% | 1 |
|
|
2016
Q1 | $5.02M | Buy |
170,000
+25,000
| +17% | +$789K | 5.76% | 10 |
|
|
2015
Q4 | $6.57M | Buy |
+145,000
| New | +$7.6M | 5.81% | 5 |
|
Casdin Capital's ONCE Position: Q4 2019 in Review
Casdin Capital sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 863,300 shares — an estimated $83.7M sold.
Casdin Capital first reported a position in ONCE in Q4 2015 and held it in 16 quarters. The position peaked at $107M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Casdin Capital reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Casdin Capital sold 863,300 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $83.7M.
- Casdin Capital first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2015 and held it in 16 quarters.
- Casdin Capital's Spark Therapeutics, Inc. Common Stock position peaked at $107M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Casdin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.